Modern Retina

Your top destination for retina-related information. We provide insights on conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, uveitis, and others. We are partnered with Ophthalmology Times.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1786791

United States

#597030

Health/Medicine

#3861

Traffic sources

Monthly visitors

Articles

Rebranded VeonGen Therapeutics announces rare pediatric disease designation for VG801

1 day ago | modernretina.com | Martin Harp

ViGeneron has rebranded to VeonGen Therapeutics to reflect its evolution into a “clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs.”In addition to the rebranding, VeonGen also announced the US Food and Drug Administration (FDA) has given Rare Pediatric Disease Designation (RPDD) to its lead program, VG801, for the treatment of ABCA4 mutation-associated retinal dystrophy.
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia

2 days ago | modernretina.com | Martin Harp

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases. Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.
Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

4 days ago | modernretina.com | Martin Harp

Ocular Therapeutix has closed enrollment in its SOL-R registrational trial of its product candidate AXPAXLI (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD). AXPAXLI is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small-molecule, multi-target tyrosine kinase inhibitor (TKI) with anti-angiogenic properties.
Innovative suprachoroidal injection reduces diabetic retinopathy complications

4 days ago | modernretina.com | David S. Boyer |Sydney M Crago

David S. Boyer, MD, discusses a new approach to treating diabetic retinopathy and macular degeneration using suprachoroidal space injections. This innovative technique offers significant advantages over traditional intravitreal injections by providing a less invasive, office-based procedure with dramatically reduced inflammatory risks. The study examined 3 dosing regimens (2.5e-11, 5e-11, and 1e-12) across different patient groups with diabetic retinopathy.
Faricimab improves vision for minority patients with diabetic macular edema

6 days ago | modernretina.com | J. Arevalo |Sydney M Crago

Johns Hopkins researcher J. Fernando Arevalo, MD, PhD, FACS, FASRS, presents ELEVATUM, a pioneering multicountry study examining faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities. The research focused on 124 patients across 40 centers in the United States, targeting individuals aged 18 and older with type 1 or type 2 diabetes.
Post hoc analysis of GATHER1 and GATHER2 data

1 week ago | modernretina.com | Lynda Charters

A post hoc analysis of the GATHER1 and GATHER2 data suggested that the ellipsoidal zone (EZ) may hold the key to identifying patients experiencing fast and slow progression of geographic atrophy (GA). This knowledge should allow for early intervention to save the photoreceptors, according to Asmita Indurkar, MD, who reported at the Association for Research in Vision and Ophthalmology 2025 annual meeting in Salt Lake City.
David Tanzer, MD, CMO of Lexitas reflects on Retina World Congress

1 week ago | modernretina.com | David Tanzer |Sydney M Crago

May 29, 2025By Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative patient care strategies. David Tanzer, MD, Lexitas Pharma Services' CMO, met up with Modern Retina® to chat during the 2025 Retina World Congress annual meeting.
Metabolomic profiling of vitreous humor reveals stage-specific biomarkers in diabetic retinopathy

1 week ago | modernretina.com | Lynda Charters

The authors of a recent study believe in the potential of metabolomic profiling for identifying stage-specific biomarkers of diabetic retinopathy (DR) in the vitreous,1 according to first author John Kim Hiller, MD, PhD, from the Center for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Institute of Clinical Medicine, Faculty of Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.
Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

1 week ago | modernretina.com | Martin Harp

The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Ocugen’s OCU410ST for the treatment of ABCA4-associated retinopathies, including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.1Previously, OCU410ST received Orphan Drug designations for the treatment of ABCA4-associated retinopathies from the FDA and European Medicines Agency.
Health care leader coalition launches Alliance for Healthcare from the Eye initiative

1 week ago | modernretina.com | Jordana Joy

During the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City held from May 3-7, a coalition of health care leaders announced the launch of the Alliance for Healthcare from the Eye (AHE), a cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics, according to a news release.1 “The eye offers a non-invasive, high-resolution window into the body’s vascular,...